Logo-ipp
Submitted: 23 Aug 2024
Revision: 10 Jan 2025
Accepted: 25 Jan 2025
ePublished: 22 Feb 2025
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Immunopathol Persa. 2025;11(2): e34472.
doi: 10.34172/ipp.2025.34472
  Abstract View: 67
  PDF Download: 27

Original

Immunohistochemical evaluation of CD10, BCL6, BCL2, MUM1 and MYC in diffuse large B-cell brain lymphoma; diagnostic and prognostic significance

Farahnaz Bidari Zerehpoosh 1 ORCID logo, Masoomeh Farahmandfar 2* ORCID logo, Guive Sharifi 3 ORCID logo, Omidvar Rezaei 4 ORCID logo, Latif Gachkar 5 ORCID logo

1 Department of Pathology, Shahid Beheshti University of Medical Sciences, Loghman Hakim Hospital, Tehran, Iran
2 Department of Pathology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Department of Neurosurgery, School of Medicine, Skull Base Research Center Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Department of Neurosurgery, School of Medicine, Skull Base Research Center Loghman Hakim Hospital Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 Department of Infectious Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
*Corresponding Author: Masoomeh Farahmandfar, Email: drmasomfar@gmail.com

Abstract

Introduction: Although the prognosis of primary central nervous system lymphoma (PCNSL), a progressive neoplasm of the central nervous system, has improved with the use of current therapies, the overall survival rate of patients is still low.

Objectives: Since the identification of factors that affect the survival of these patients can help physicians choose the best treatment and prognosis, this study aimed to investigate the diagnostic and prognostic significance of immunohistochemical biomarkers in patients with diffuse large B-cell lymphoma (DLBCL), as the most common type of PCNSL.

Patients and Methods: In this descriptive-cross-sectional, 30 histological block samples from patients diagnosed with DLBCL were subjected to tissue preparation and immunohistochemical staining with multiple myeloma oncogene-1 (MUM1), B cell lymphoma-6 (BCL-6), B cell lymphoma-2 (BCL-2), cluster differentiation 10 (CD10), and MYC antibodies, and their expression rates were determined subsequently. Patients’ characteristics, including survival status and survival time after diagnosis, were extracted from patients’ records.

Results: Immunohistochemistry positivity for MUM1, BCL-6, BCL-2, CD10, and MYC biomarkers were seen in 25 (83%), 21 (70%), 25 (83%), 2 (7%), 25 (83%) and 0 (0%), respectively. According to the Hans algorithm, 24 patients (80%) were activated B cell (ABC) and 6 patients (20 %) were germinal center B cell (GCB). Totally, 23 (77%) patients have died during the study period. The mean survival time of patients was 12 months (95% CI: 14.47-33.24). There was no significant difference in death rate for different categories of variables such as demographic characteristics, DLBCL subgroup, and biomarker positive rates (P>0.05). According to the univariate cox model, the immunohistochemistry (IHC) reactivity rate for the studied biomarkers did not significantly affect the survival. In contrast, chemotherapy and radiotherapy reduce the hazard of death by 72% and 65%, respectively.

Conclusion: The results of the present study revealed that the expression rate of MUM1, BCL-6, BCL-2, CD10, and MYC could not be used as a proper prognostic biomarker for DLBCL patients.


Citation: Bidari Zerehpoosh F, Farahmandfar M, Sharifi G, Rezaei O, Gachkar L. Immunohistochemical evaluation of CD10, BCL6, BCL2, MUM1 and MYC in diffuse large B-cell brain lymphoma; diagnostic and prognostic significance. Immunopathol Persa. 2025;11(2):e34472. DOI:10.34172/ipp.2025.34472.
First Name
Last Name
Email Address
Comments
Security code


Abstract View: 68

Your browser does not support the canvas element.


PDF Download: 27

Your browser does not support the canvas element.